Division of Endocrinology, Department of Pediatrics, Emory University, Atlanta, Georgia.
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, Georgia.
Pediatr Blood Cancer. 2019 Dec;66(12):e27981. doi: 10.1002/pbc.27981. Epub 2019 Sep 10.
Providers often rely on self-reported ovarian function in adolescent and young adult (AYA)-aged childhood cancer survivors when making clinical decisions. This study described reported menstrual patterns and the agreement between respondent-reported and biochemical premature ovarian insufficiency (POI) in this population.
This was a cross-sectional study of survivors (or their parent proxy) aged 13-21.9 years who received gonadotoxic therapy and were enrolled in a longitudinal health survey. Participants reported menstrual regularity, hormone-replacement therapy (HRT) use, and ovarian dysfunction. Respondent-reported POI was defined as the survivor taking HRT for ovarian failure or having been told she had ovarian failure. Biochemical POI was defined as follicle-stimulating hormone (FSH) level ≥40 mIU/mL. The agreement between respondent-reported and biochemical POI was determined using Cohen's kappa coefficient (κ) and analyzed by demographic and clinical factors.
Among 182 AYA-aged survivors (72.5% non-Hispanic White, 46.7% leukemia survivors), 14.8% reported requiring HRT to have menses but 55.5% reported regular menses without HRT use. Among survivors with FSH measurements (n = 130), 17.7% reported POI whereas 18.5% had FSH ≥40 mIU/mL (κ = 0.66, sensitivity 70.8%, specificity 94.3%). The highest agreement between respondent-reported and biochemical POI was with young adult self-report (κ = 0.78) and survivors with >5 survivor clinic (κ = 0.83) and/or >5 endocrinologist (κ = 1.00) visits.
The majority of AYA-aged survivors reported having regular menses without HRT support. The accuracy of respondent-reported POI increased with repeated survivor clinic or endocrinologist visits, highlighting the importance of continued education. Survivors must be informed about their ovarian function to enable them to advocate for their reproductive health.
在为青少年和年轻成年(AYA)期癌症幸存者做出临床决策时,医生通常依赖于自我报告的卵巢功能。本研究描述了该人群的报告月经模式和受访者报告与生物化学性卵巢早衰(POI)之间的一致性。
这是一项针对年龄在 13-21.9 岁、接受性腺毒性治疗并参加纵向健康调查的幸存者(或其父母代理人)的横断面研究。参与者报告了月经规律、激素替代疗法(HRT)使用情况和卵巢功能障碍情况。受访者报告的 POI 定义为幸存者因卵巢衰竭而服用 HRT 或被告知卵巢衰竭。生物化学性 POI 定义为卵泡刺激素(FSH)水平≥40 mIU/mL。使用 Cohen's kappa 系数(κ)确定受访者报告和生物化学性 POI 之间的一致性,并根据人口统计学和临床因素进行分析。
在 182 名 AYA 期幸存者(72.5%为非西班牙裔白人,46.7%为白血病幸存者)中,14.8%报告需要 HRT 才能来月经,但 55.5%报告在不使用 HRT 的情况下月经规律。在有 FSH 测量值的幸存者中(n=130),17.7%报告 POI,而 18.5%的 FSH≥40 mIU/mL(κ=0.66,敏感性 70.8%,特异性 94.3%)。受访者报告和生物化学性 POI 之间的一致性最高是在年轻成年自我报告中(κ=0.78),以及幸存者就诊次数≥5 次的诊所(κ=0.83)和/或就诊次数≥5 次的内分泌科医生(κ=1.00)。
大多数 AYA 期幸存者报告在没有 HRT 支持的情况下月经规律。受访者报告 POI 的准确性随着幸存者就诊次数或内分泌科医生就诊次数的增加而提高,这突出了持续教育的重要性。必须告知幸存者有关其卵巢功能的信息,以使他们能够为自己的生殖健康辩护。